The Vanderbilt-Ingram Cancer Center is helping pioneer a new treatment that reengineers T-cells so they seek and destroy cancer cells. Dr. Olalekan Oluwole, an oncologist, is helping spearhead an ...

EPFL researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. The work, covered in two papers, turns the previously lab-based method into a ...

Clinical effectiveness of immune therapies of solid tumors requires a) the induction or expansion of T cells able of recognizing multiple variants of cancer cells present in each cancer patient, and b ...

A new study suggest that using CXCL9 and CXCL10-producing dendritic cells alongside immunotherapy can be a promising strategy to overcome treatment resistance and improve clinical outcomes for ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Diakonos Oncology reports that an interim analysis of a Phase I open label trial of its dendritic cell vaccine (DOC1021) showed substantially increased survival of glioblastoma multiforme (GBM) ...

Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...

The personalized immunotherapy works by activating the body’s natural immune response to target and eliminate cancer cells. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

The immune system consists of inflammatory and regulatory T cells (Tregs) that promote or dampen immune activity, respectively. These cells react to specific antigens that specialized cells like ...